Voyager Therapeutics and AbbVie, already partners developing gene therapies for Alzheimer’s disease, are now expanding their alliance to include Parkinson’s.
AbbVie (NYSE: ABBV) is paying Cambridge, MA-based Voyager (NASDAQ: VYGR) $65 million up front under the new deal. Gene therapies use viruses to carry the genetic instructions into cells. The agreement calls for Voyager to develop the viral vectors that will transport into the brain the genes that code for the production of therapeutic antibodies. These antibodies would target a protein called alpha-synuclein, which forms clumps in the brain that are characteristic of Parkinson’s and other neurodegenerative diseases, such… Read more »
